Halo Labs Launches New Instruments for Protein, Cell, and Gene Therapy Developers

Aura PTx analyzes degraded excipients in protein therapeutics, and Aura+ is an all-in-one drug product quality tool for mAb, cell, and gene therapy

See more here


ASHP Innovation Center and Bainbridge Health Collaborate to Improve Patient Safety, Increase Use of Standardized Medication Concentrations in Health Systems

See more here


Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 

Immunome has received a clinical hold letter from the FDA requesting further information related to the preparation and administration of the IMM-BCP-01 cocktail at clinical sites

Immunome expects to provide the requested information soon and remains on track to generate top-line clinical data for IMM-BCP-01 in the first half of 2022

Reporting of IMM-BCP-01 activity against the Omicron variant in live virus testing by an external laboratory also remains on track for this month

See more here


Annovis Bio Enhances Leadership Team with Two Senior Appointments

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations

Company Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & Development

See more here


VESTECK named “Top 10 Cardiovascular Device Company for 2021” by MedTech Outlook Magazine

See more here


Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

See more here


Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

– Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD

– Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo 

– Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking 

See more here


Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases

See more here


ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers

Clinical trials for ImmunoGenesis drug candidates to initiate in 2022

See more here